

Bruce E Strober

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6412284/publications.pdf>

Version: 2024-02-01

187
papers

13,344
citations

26630

56
h-index

23533

111
g-index

191
all docs

191
docs citations

191
times ranked

8820
citing authors

#	ARTICLE	IF	CITATIONS
1	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. Journal of the American Academy of Dermatology, 2008, 58, 106-115.	1.2	796
2	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. New England Journal of Medicine, 2010, 362, 118-128.	27.0	773
3	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine, 2015, 373, 1318-1328.	27.0	656
4	The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell, 1994, 79, 119-130.	28.9	622
5	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 2019, 80, 1029-1072.	1.2	542
6	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet, The, 2018, 392, 650-661.	13.7	457
7	Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions. PLoS ONE, 2008, 3, e2719.	2.5	388
8	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology, 2008, 58, 1031-1042.	1.2	383
9	Community differentiation of the cutaneous microbiota in psoriasis. Microbiome, 2013, 1, 31.	11.1	353
10	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5â€¦years of follow-up. British Journal of Dermatology, 2013, 168, 844-854.	1.5	350
11	Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. Journal of the American Academy of Dermatology, 2009, 60, 824-837.	1.2	289
12	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. British Journal of Dermatology, 2012, 167, 668-677.	1.5	281
13	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, 2019, 80, 1073-1113.	1.2	281
14	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. British Journal of Dermatology, 2007, 157, 649-655.	1.5	273
15	Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 864-71.	7.4	259
16	Functional Interactions between the hBRM/hBRG1 Transcriptional Activators and the pRB Family of Proteins. Molecular and Cellular Biology, 1996, 16, 1576-1583.	2.3	246
17	Molecular Analysis of Fungal Microbiota in Samples from Healthy Human Skin and Psoriatic Lesions. Journal of Clinical Microbiology, 2006, 44, 2933-2941.	3.9	223
18	Hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2020, 82, 1045-1058.	1.2	202

#	ARTICLE	IF	CITATIONS
19	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology, 2020, 82, 1445-1486.	1.2	184
20	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. British Journal of Dermatology, 2008, 159, 322-330.	1.5	176
21	A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. Journal of Investigative Dermatology, 2012, 132, 304-314.	0.7	157
22	Consensus Guidelines for the Management of Plaque Psoriasis. Archives of Dermatology, 2012, 148, 95.	1.4	148
23	Topical Chemotherapy in Cutaneous T-cell Lymphoma. JAMA Dermatology, 2013, 149, 25.	4.1	147
24	Joint AADâ€“NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology, 2021, 84, 432-470.	1.2	135
25	National Psoriasis Foundation Clinical Consensus on Disease Severity. Archives of Dermatology, 2007, 143, 239-42.	1.4	132
26	Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 2010, 62, 291-299.	1.2	132
27	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, 2020, 82, 161-201.	1.2	129
28	Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. British Journal of Dermatology, 2011, 165, 661-668.	1.5	128
29	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
30	A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. British Journal of Dermatology, 2012, 167, 649-657.	1.5	116
31	An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Current Medical Research and Opinion, 2008, 24, 1529-1538.	1.9	115
32	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal of the American Academy of Dermatology, 2017, 76, 432-440.e17.	1.2	111
33	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of Dermatology, 2017, 76, 1093-1102.	1.2	110
34	From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology, 2008, 58, 94-105.	1.2	109
35	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology, 2019, 81, 775-804.	1.2	105
36	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. Journal of the American Academy of Dermatology, 2012, 66, 731-741.	1.2	101

#	ARTICLE	IF	CITATIONS
37	Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. Journal of the American Academy of Dermatology, 2005, 52, 1082-1084.	1.2	100
38	Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 77-82.e7.	1.2	96
39	Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety, 2019, 42, 751-768.	3.2	93
40	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 2219-2229.	27.0	93
41	Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. British Journal of Dermatology, 2013, 169, 992-999.	1.5	84
42	Off-Label Dermatologic Uses of Anti-TNF- α Therapies. Journal of Cutaneous Medicine and Surgery, 2005, 9, 296-302.	1.2	83
43	Folate supplementation during methotrexate therapy for patients with psoriasis. Journal of the American Academy of Dermatology, 2005, 53, 652-659.	1.2	82
44	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the American Academy of Dermatology, 2018, 78, 70-80.	1.2	78
45	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry). JAMA Dermatology, 2021, 157, 1071-1079.	1.2	78
46	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, 2018, 78, 323-332.	1.2	73
47	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal of the American Academy of Dermatology, 2011, 64, 671-681.	1.2	69
48	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. British Journal of Dermatology, 2018, 179, 1205-1207.	1.5	69
49	Hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2020, 82, 1061-1082.	1.2	69
50	Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. Journal of Drugs in Dermatology, 2010, 9, 928-37.	0.8	69
51	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2017, 177, 1562-1574.	1.5	68
52	Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opinion on Biological Therapy, 2013, 13, 1039-1047.	3.1	63
53	Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology and Therapy, 2019, 9, 5-18.	3.0	63
54	PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal of Drugs in Dermatology, 2012, 11, 1210-7.	0.8	63

#	ARTICLE	IF	CITATIONS
55	The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. American Journal of Clinical Dermatology, 2011, 12, 321-337.	6.7	62
56	Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. British Journal of Dermatology, 2012, 167, 1374-1381.	1.5	59
57	Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. American Journal of Medicine, 2014, 127, 1148-1153.	1.5	59
58	Successful Treatment of Subacute Lupus Erythematosus With Ustekinumab. Archives of Dermatology, 2011, 147, 896.	1.4	57
59	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1252-1261.	2.4	56
60	Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. Journal of the American Academy of Dermatology, 2012, 66, 317-322.	1.2	55
61	Conventional systemic agents for psoriasis. A systematic review. Journal of Rheumatology, 2006, 33, 1442-6.	2.0	55
62	Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris. Archives of Dermatology, 2006, 142, 605-12.	1.4	53
63	The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. International Journal of Dermatology, 2014, 53, 714-722.	1.0	53
64	A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal of the American Academy of Dermatology, 2006, 55, 40-46.	1.2	50
65	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 2015, 72, 436-439.e1.	1.2	49
66	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Journal of the American Academy of Dermatology, 2020, 83, 96-103.	1.2	47
67	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa-1 and UltimMa-2 studies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2830-2838.	2.4	46
68	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment, 2017, 28, 492-499.	2.2	44
69	Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open, 2019, 9, e027535.	1.9	44
70	Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. Journal of Dermatological Treatment, 2006, 17, 343-352.	2.2	43
71	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. British Journal of Dermatology, 2017, 177, 1537-1551.	1.5	43
72	Alefacept for Severe Alopecia Areata. Archives of Dermatology, 2009, 145, 1262-6.	1.4	40

#	ARTICLE	IF	CITATIONS
73	Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal of Dermatology, 2010, 162, 1349-1358.	1.5	39
74	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 897-905.	1.2	38
75	Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Journal of Drugs in Dermatology, 2017, 16, 801-808.	0.8	38
76	Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatology and Therapy, 2021, 11, 529-541.	3.0	36
77	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. British Journal of Dermatology, 2021, 185, 1146-1159.	1.5	36
78	A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal of the American Academy of Dermatology, 2009, 61, S1-S46.	1.2	35
79	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. International Journal of Dermatology, 2016, 55, 401-407.	1.0	34
80	Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 886-892.	2.4	34
81	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. British Journal of Dermatology, 2019, 180, 67-75.	1.5	33
82	Comparison of clinical and pharmacokinetic profiles of etanercept 25-mg twice weekly and 50-mg once weekly in patients with psoriasis. British Journal of Dermatology, 2007, 156, 138-142.	1.5	32
83	Alefacept in the treatment of psoriatic nail disease: A small case series. Journal of the American Academy of Dermatology, 2005, 52, 1101-1102.	1.2	31
84	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy, 2022, 12, 495-510.	3.0	30
85	Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. British Journal of Dermatology, 2004, 150, 581-588.	1.5	29
86	Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology, 2016, 33, 142-149.	0.9	29
87	Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary. Value in Health, 2013, 16, 1014-1022.	0.3	28
88	Secukinumab sustains early patient-reported outcome benefits through 1-year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology, 2017, 76, 655-661.	1.2	28
89	Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatologic Therapy, 2007, 20, 270-276.	1.7	26
90	Current and Future Oral Systemic Therapies for Psoriasis. Dermatologic Clinics, 2015, 33, 91-109.	1.7	26

#	ARTICLE	IF	CITATIONS
91	Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry. <i>Dermatologic Therapy</i> , 2021, 34, e14808.	1.7	26
92	Etanercept for the treatment of psoriasis: combination therapy with other modalities. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 270-2.	0.8	26
93	Treatment of atopic dermatitis in pregnancy. <i>Dermatologic Therapy</i> , 2013, 26, 293-301.	1.7	24
94	Efalizumab for the treatment of refractory hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 1090-1091.	1.2	23
95	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85.	1.5	23
96	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 31, 333-341.	2.2	23
97	Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. <i>British Journal of Dermatology</i> , 2013, 168, 210-212.	1.5	22
98	Successful Treatment of Psoriasis and Psoriatic Arthritis With Etanercept and Methotrexate in a Patient Newly Unresponsive to Infliximab. <i>Archives of Dermatology</i> , 2004, 140, 366.	1.4	20
99	Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. <i>Dermatology</i> , 2011, 222, 36-48.	2.1	20
100	Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report. <i>JAAD Case Reports</i> , 2015, 1, 3-4.	0.8	20
101	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. <i>Dermatology and Therapy</i> , 2012, 2, 1.	3.0	18
102	Management of psoriasis in pregnancy. <i>Dermatologic Therapy</i> , 2013, 26, 285-292.	1.7	17
103	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013, 6, S2-S20.	0.1	17
104	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). <i>British Journal of Dermatology</i> , 2022, 187, 866-877.	1.5	17
105	No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, e105-e107.	1.5	16
106	Similar Names for Similar Biologics. <i>BioDrugs</i> , 2014, 28, 439-444.	4.6	14
107	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. <i>International Journal of Dermatology</i> , 2016, 55, e147-55.	1.0	14
108	Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1701-1706.	2.4	13

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 587-596.	1.6	13
110	Eyelash hypertrichosis in a patient treated with topical latanoprost. <i>Cutis</i> , 2001, 67, 109-10.	0.3	13
111	Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. <i>Dermatology and Therapy</i> , 2022, 12, 381-393.	3.0	13
112	Anti-interleukin-17 treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 311-315.	2.2	12
113	Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2126-2133.	2.4	12
114	Off-Label Dermatologic Uses of Anti-TNF- α Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 296-302.	1.2	11
115	Folate with methotrexate: big benefit, questionable cost. <i>British Journal of Dermatology</i> , 2007, 157, 213-213.	1.5	11
116	Tinea versicolor associated with etanercept therapy. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S99-S100.	1.2	11
117	Efalizumab-Associated Guillain-Barré Syndrome. <i>Archives of Dermatology</i> , 2008, 144, 1396-7.	1.4	11
118	Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2021, 32, 302-309.	2.2	11
119	Why Biologic Therapies Sometimes Lose Efficacy. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2016, 35, S78-S80.	1.6	11
120	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	2.4	11
121	Reconsidering liver biopsies during methotrexate therapy. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 893-894.	1.2	10
122	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. <i>Dermatology and Therapy</i> , 2012, 2, 2.	3.0	10
123	Psoriasis in adults and children: Kids are not just little people. <i>Clinics in Dermatology</i> , 2016, 34, 717-723.	1.6	10
124	Methotrexate treatment of generalized granuloma annulare: a retrospective case series. <i>Journal of Dermatological Treatment</i> , 2018, 29, 720-724.	2.2	10
125	Clinical trials: Kids are not just little people. <i>Clinics in Dermatology</i> , 2017, 35, 583-593.	1.6	9
126	Apremilast mechanism of efficacy in systemic-naïve patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. <i>Journal of Dermatological Science</i> , 2019, 96, 126-133.	1.9	9

#	ARTICLE	IF	CITATIONS
127	PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 131-138.	1.2	9
128	Methotrexate and Cyclosporine in Psoriasis Revisited. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S27-S30.	1.6	9
129	The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas™ Psoriasis Registry. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 71-78.	0.7	9
130	Interferon beta-1a-induced morphea. <i>JAAD Case Reports</i> , 2015, 1, 15-17.	0.8	8
131	Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. <i>Value in Health</i> , 2017, 20, 1174-1179.	0.3	8
132	A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. <i>Dermatology and Therapy</i> , 2021, 11, 1851-1860.	3.0	8
133	Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2022, 158, 142.	4.1	8
134	Methotrexate-Induced Liver Toxicity. <i>JAMA Dermatology</i> , 2014, 150, 862.	4.1	7
135	The treatment of psoriasis with etanercept. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2005, 24, 28-36.	1.6	6
136	The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 28-34.	1.6	6
137	Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. <i>British Journal of Dermatology</i> , 2016, 174, 212-215.	1.5	6
138	Methotrexate and psoriasis: Consensus conference. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1179.	1.2	5
139	How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 569-572.	1.2	5
140	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 699-709.	6.7	5
141	Understanding Therapeutic Pathways and Comorbidities in Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S20-S23.	1.6	5
142	Successful Treatment of Plaque Psoriasis With Self-administered Subcutaneous Alefacept. <i>Archives of Dermatology</i> , 2005, 141, 1602.	1.4	4
143	Ethical considerations when prescribing biologics in dermatology. <i>Clinics in Dermatology</i> , 2012, 30, 492-495.	1.6	4
144	Dose Response and Pharmacokinetics of Tofacitinib (CPâ€690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-8.	2.5	4

#	ARTICLE	IF	CITATIONS
145	The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. <i>Dermatology and Therapy</i> , 2021, 11, 1079-1083.	3.0	4
146	Cutaneous <i>Bacillus anthracis</i> Infection. <i>New England Journal of Medicine</i> , 2001, 345, 1646-1647.	27.0	3
147	Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 333-335.	1.2	3
148	Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021, 11, 253-263.	3.0	3
149	Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. <i>British Journal of Dermatology</i> , 2021, 185, 840-842.	1.5	3
150	New Therapies for Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2016, 35, S71-S73.	1.6	3
151	Getting personal about skin: Realizing precision medicine in dermatology. <i>Dermatological Reviews</i> , 2021, 2, 289-295.	0.5	3
152	Treatment of refractory dissecting cellulitis of the scalp with guselkumab: Case report. <i>Journal of Dermatology & Dermatologic Surgery</i> , 2020, 24, 52.	0.2	3
153	Alefacept in the treatment of psoriatic nail disease. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P151.	1.2	2
154	Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2567-2569.	0.7	2
155	Rethinking eligibility creep. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 165-167.	1.2	2
156	Janus Kinase Inhibitors. , 2018, , 187-198.		2
157	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 1484-1487.	1.5	2
158	The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1533-1535.	1.2	2
159	Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 93-98.	0.7	2
160	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S5-S29.	0.1	2
161	Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. <i>Dermatology and Therapy</i> , 2022, 12, 1351-1365.	3.0	2
162	On multiple courses of alefacept. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 916-917.	1.2	1

#	ARTICLE	IF	CITATIONS
163	Methotrexate and psoriasis: Consensus conference. Journal of the American Academy of Dermatology, 2012, 66, 689-690.	1.2	1
164	Biologic therapy for psoriasis: early response implies future success. British Journal of Dermatology, 2013, 169, 1178-1179.	1.5	1
165	Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data. Value in Health, 2014, 17, A288.	0.3	1
166	Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 167-174.	0.7	1
167	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. Journal of Psoriasis and Psoriatic Arthritis, 2017, 2, 73-80.	0.7	1
168	Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review. Journal of the American Academy of Dermatology, 2021, 85, 726-728.	1.2	1
169	Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. Journal of Dermatological Treatment, 2020, 32, 1-9.	2.2	1
170	Comparative Effectiveness Studies for Psoriasis—The Methods Matter. JAMA Dermatology, 2020, 156, 253.	4.1	1
171	Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 12-15.	0.7	1
172	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2015, 8, S4-S26.	0.1	1
173	Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal of Dermatological Treatment, 0, , 1-9.	2.2	1
174	Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Journal of the American Academy of Dermatology, 2004, 50, P147.	1.2	0
175	Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy. Journal of the American Academy of Dermatology, 2004, 50, P147.	1.2	0
176	Evaluation of the cutaneous microbiome in psoriasis. Nature Precedings, 2010, , .	0.1	0
177	Interleukin-23 inhibition for the treatment of psoriasis: the next frontier for high-efficacy biologic therapy. British Journal of Dermatology, 2015, 173, 887-888.	1.5	0
178	Measurement Properties of the patient-reported Psoriasis Symptom inventory daily diary in patients with moderate to severe Plaque Psoriasis. Value in Health, 2015, 18, A183.	0.3	0
179	060 Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials. Journal of Investigative Dermatology, 2016, 136, S170.	0.7	0
180	Core Outcome Sets for Psoriasis Clinical Trials. JAMA Dermatology, 2018, 154, 1135.	4.1	0

#	ARTICLE	IF	CITATIONS
181	Letter from the New Editor in Chief. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 81-81.	0.7	0
182	Phosphodiesterase-4 and Janus Kinase Inhibitors. , 2021, , 199-208.e3.		0
183	How to Best Define Psoriasis Severity: A New Consensus Statement From the International Psoriasis Council. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 6-7.	0.7	0
184	POS1032â€¦EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Annals of the Rheumatic Diseases, 2021, 80, 788-789.	0.9	0
185	Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and ultraviolet light.. Journal of Clinical Oncology, 2010, 28, 8566-8566.	1.6	0
186	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2014, 7, S5-S22.	0.1	0
187	Gender Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032210998.	0.7	0